Christopher Gibson Sells 50,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Christopher Gibson sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $7.73, for a total value of $386,500.00. Following the completion of the transaction, the chief executive officer now directly owns 863,524 shares in the company, valued at $6,675,040.52. The transaction was disclosed in a filing with the SEC, which is available at this link.

Christopher Gibson also recently made the following trade(s):

• On Wednesday, April 3rd, Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.84, for a total value of $353,600.00.
• On Thursday, March 28th, Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $10.10, for a total value of $404,000.00.
• On Wednesday, March 6th, Christopher Gibson sold 36,319 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $11.86, for a total transaction of $430,743.34.
• On Wednesday, February 7th, Christopher Gibson sold 48,272 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.22, for a total transaction of $445,067.84.

Recursion Pharmaceuticals Trading Up 0.6 %

Shares of Recursion Pharmaceuticals stock opened at $8.84 on Friday. Recursion Pharmaceuticals, Inc. has a 1-year low of $4.80 and a 1-year high of $16.75. The company’s fifty day simple moving average is $9.88 and its 200-day simple moving average is $9.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.06. The company had revenue of $10.89 million for the quarter, compared to the consensus estimate of $12.37 million. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. As a group, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in RXRX. National Bank of Canada FI lifted its holdings in Recursion Pharmaceuticals by 90.9% during the fourth quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after purchasing an additional 1,500 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in shares of Recursion Pharmaceuticals by 6.2% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 33,002 shares of the company’s stock valued at $252,000 after buying an additional 1,938 shares in the last quarter. Wedmont Private Capital boosted its holdings in Recursion Pharmaceuticals by 11.8% in the 1st quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock worth $172,000 after buying an additional 2,000 shares during the period. Allspring Global Investments Holdings LLC increased its stake in Recursion Pharmaceuticals by 25.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 10,123 shares of the company’s stock worth $77,000 after buying an additional 2,050 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. bought a new stake in Recursion Pharmaceuticals during the first quarter valued at about $26,000. 89.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. KeyCorp boosted their target price on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Monday, March 4th. Needham & Company LLC reissued a “buy” rating and issued a $17.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday, April 9th. Finally, TD Cowen started coverage on Recursion Pharmaceuticals in a research report on Friday, January 26th. They issued a “market perform” rating on the stock. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $12.75.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.